Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) Research & Development (2016 - 2024)

Rockwell Medical (RMTI) has disclosed Research & Development for 15 consecutive years, with $1000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Research & Development fell 99.4% year-over-year to $1000.0, compared with a TTM value of $1000.0 through Sep 2025, down 99.46%, and an annual FY2024 reading of $19000.0, down 98.28% over the prior year.
  • Research & Development was $1000.0 for Q4 2024 at Rockwell Medical, down from $18000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $2.4 million in Q2 2021 and bottomed at $1000.0 in Q4 2024.
  • Average Research & Development over 5 years is $1.0 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 266.4% in 2020, then plummeted 99.4% in 2024.
  • Year by year, Research & Development stood at $1.9 million in 2020, then fell by 27.49% to $1.4 million in 2021, then tumbled by 90.14% to $137000.0 in 2022, then grew by 22.63% to $168000.0 in 2023, then tumbled by 99.4% to $1000.0 in 2024.
  • Business Quant data shows Research & Development for RMTI at $1000.0 in Q4 2024, $18000.0 in Q1 2024, and $168000.0 in Q4 2023.